Madison, WI, January 1, 2022 — Elephas Biosciences Corporation (Elephas), a live tumor imaging company developing novel cancer diagnostic solutions, announced today the appointment of Dr. Hinco Gierman as VP Precision Oncology. Dr. Gierman, previously a scientific consultant to Elephas, will continue working with leadership on advancing the company’s platform.
Dr. Gierman has over 20 years of experience in oncology and genomics across academia and industry. After earning his PhD in oncology & genomics from the University of Amsterdam, Dr. Gierman worked as a postdoctoral research fellow on the genetics of age-related disease at Stanford University.
“From day one, it has been Elephas’ goal to improve outcomes for cancer patients,” stated Maneesh Arora, founder and CEO of Elephas. “Bringing Hinco onboard strengthens the wealth of deep oncology experience that already exists at the company, and I am excited to have him join the leadership team.”
Most recently, Dr. Gierman served as VP of Product Development at Integra Connect, where he led the development of an enterprise cancer patient suite of analytical software used by clinicians and researchers in biopharma. Previously, Dr. Gierman lead the scientific enterprise software team at Illumina and worked with twelve of the top twenty five pharma organizations during his four years there.
“What attracted me most to Elephas is that we are truly trying to combine different insights into the tumor, including genomics, proteomics, advanced imaging, and AI. Only by doing this will we be able to truly understand what happens when a patient’s tumor is treated and provide the best treatment guidance.”
Dr. Gierman has over 20 scientific publications on genetics and oncology and his publications have been cited over 1,400 times.
About Elephas
Cancer is a leading cause of death worldwide, with the number of patients projected to triple by 2060. Despite a significant increase in the number of available immunotherapies, only 1 in 5 patients receiving immunotherapy obtain a response and many who may respond are not eligible for therapy due to lack of accurate predictive biomarkers. With the mission to tackle the massive oncology dilemma, Elephas has developed an ex-vivo platform to assess how live patient biopsies respond to immunotherapies. By preserving the native tumor microenvironment from a live core needle biopsy and using a novel method to address tumor heterogeneity, the Elephas Live platform enables a real-time characterization of immune response. To learn more, visit us at www.elephas.com or follow us on LinkedIn.
Contact
John Fitzpatrick
marketing@elephas.com
